How it all started

In 1789, the English physician William Withering, inspired by an old herb woman in Shropshire, published his seminal monograph, “An account of the Foxglove and some of its medical uses with practical remarks on dropsy, and other diseases,” (1) in which he described the clinical effects of an extract of the foxglove plant on patients with a condition that he called dropsy; thus, the first, albeit potentially toxic, remedy for heart failure was established. Withering observed that after ingesting his herbal extract, patients with dropsy started to urinate and edema regressed. He realized that this condition was due to water retention, but he was far from today’s understanding of heart failure.

With the advent of imaging techniques, initially chest X-ray imaging, then ventriculography, echocardiography, and eventually nuclear techniques and cardiac magnetic resonance imaging, many patients with such a condition were found to have large hearts with poor pump function. As no other parameter was available, changes on the volume of the ventricles, i.e., ejection fraction, became the center of interest for the assessment of patients with what we know today as heart failure. Since then the left ventricular ejection fraction (LVEF) was the focus in this patient population—indeed, MACE can only be reduced significantly if a large number of events are to be expected—and a low LVEF undoubtedly predicts MACE (Fig. 1) (2).

The first trial was the CONSENSUS Trial that tested enalapril, an angiotensin-converting enzyme (ACE) inhibitor in patients with severe heart failure, showing a marked reduction in MACE and mortality (3). Several other trials have investigated ACE inhibitors with similar results in lower-risk patients with heart failure. Initially, beta blockers were considered contraindicated in heart failure until a courageous pioneer, Finn Waagstein et al. (4), from Göteborg, Sweden, provided evidence that it may actually be beneficial. Indeed, heart failure leads to an overactivation of the sympathetic nervous system that may be detrimental for the heart and circulation. Indeed, against all odds, a series of trials with metoprolol (5), bisoprolol (6), and carvedilol (7, 8) all showed marked reductions in MACE and mortality. Finally, mineralocorticoid receptor antagonists, such as spironolactone (9) and later eplerenone (10), further reduced death and hospitalizations. This was the standard guideline therapy until cardiac resynchronization therapy (CRT) provided devices that are able to improve symptoms and outcomes in patients with heart failure (11). More recently, new drugs such as angiotensin-neprilysin inhibitors [ARNI (12)] and sodium-glucose transport type 2 inhibitors such as empagliflozin (13) or dapagliflozin (14) showed remarkable additional beneficial effects on top of what have been achieved so far in patients with heart failure, regardless of the presence or absence of diabetes. Finally, cyclic guanylyl cyclase activators provided small reduction in MACE (15).

While all these interventions inhibited mainly neurohumoral activation and peripheral vasoconstriction and thereby unloaded the heart and/or reduced renal water and sodium retention,
all attempts to stimulate the failing heart, not only with phosphodiesterase inhibitors (16), but also with other compounds, counterintuitively increased, rather than decreased, mortality despite their beneficial hemodynamic and symptomatic effects. In contrast, in a most recent trial, the novel cardiac myosin activator Omecamtiv Mecarbil improved cardiac performance on top of the standard therapy, but the effect size on MACE was undesirably small (17). Nevertheless, the management of patients with heart failure with reduced ejection fraction (HFrEF) is a true achievement that led to a marked improvement of the quality of life of such patients and clinical outcomes, with a continuously declining incidence of heart failure hospitalizations, MACE, and mortality, including sudden death (18).

**From a failing heart to a stiff heart**

Moreover, patients with heart failure may have normal or near-normal LVEF with typical symptoms such as breathlessness, reduced exercise capacity, as well as pulmonary and peripheral edema. Although outcomes are quite better in heart failure with preserved ejection fraction (HFpEF) than in HFrEF, these conditions are still associated with a significant number of MACE and death (Fig. 1) (19). Therefore, the most recent ESC Guidelines on the Management of Acute and Chronic Heart Failure, published in 2016, suggested to classify patients with heart failure into those with HFpEF, heart failure with mid-range ejection fraction (HFmrEF), and HFrEF (Table 1) (20).

However, while classical medications and CRT were a real success in patients with HFrEF, all these measures were not effective in patients with HFpEF (21). Similarly, the TopCat trial using spironolactone in patients with HFpEF did not attain its primary end point (22). However, a subanalysis revealed that those with ejection fraction <60% did indeed benefit from spironolactone, while those with true HFpEF, i.e., ejection fractions >60%, did not (Fig. 2) (23).

Similarly, the most recent PARAGON Trial using ARNI provided neutral results overall, except in patients with HFmrEF (24, 25), suggesting that these patients have an early or mild form of HFrEF rather than a specific condition such as HFmrEF or even HFpEF. Thus, the initial categorization needs to be reconsidered based on these recent trials.

**From lumping to splitting**

Initially, as we saw, all patients with HFrEF were lumped together, regardless of their etiology, be it ischemic or non-ischemic in nature—be it ischemic or non-ischemic in nature—but it worked so far. However, it was not a personalized approach, as it did not consider the underlying cause of heart failure, individual characteristics, specific natural course, and MACE risk of a patient. Thus, we must move from lumping to splitting to develop a more individualized approach in the management of HFrEF (26).

Indeed, categorization of patients with reduced pump function based on LVEF alone is a very crude criterion. In fact, LVEF

---

### Table 1. Categorization of heart failure according to the ESC Guidelines on the Management of Acute and Chronic Heart Failure (20)

| Type of HF | HFrEF (Symptoms±signs* LVEF <40%) | HFmrEF (Symptoms±signs* LVEF 40-49%) | HFpEF (Symptoms±signs* LVEF ≥50%) |
|-----------|-----------------------------------|-------------------------------------|----------------------------------|
| Criteria  | 1. Elevated levels of natriuretic peptides*; 2. At least one additional criterion: a. Relevant structural heart disease (LVH and/or LAE). b. Diastolic dysfunction (for details see section 4.3.2). | 1. Elevated levels of natriuretic peptides*; 2. At least one additional criterion: a. Relevant structural heart disease (LVH and/or LAE). b. Diastolic dysfunction (for details see section 4.3.2). | |

*Signs may not be present in the early stages of HF (especially in HFpEF) and in patients treated with diuretics. LVEF - left ventricular ejection fraction; HF - heart failure; HFrEF - heart failure with reduced ejection fraction; HFmrEF - heart failure with mid-range ejection fraction; HFpEF - heart failure with preserved ejection fraction.
only describes one aspect of the phenotype, i.e., the change in the volume during the cardiac cycle, and does not reflect the pump function of the heart. For instance, LVEF may grossly overestimate the true pump function in the presence of moderate and, in particular, severe mitral regurgitation. Furthermore, a classification based only on LVEF does not consider the underlying cause of heart failure, e.g., toxins, genetics, and hemodynamics, which markedly affect clinical outcomes and the effectiveness of heart failure therapy. For instance, patients with HFrEF who underwent chemotherapy do not respond well to current treatment modalities, while other forms of dilated cardiomyopathy do.

**From phenotype to genotype**

Indeed, genetic maps that summarize genetic mutations of patients with various forms of dilated cardiomyopathy have been published (Fig. 3) (27). These maps made it possible to perform a more personalized evaluation of patients with dilated cardiomyopathy. Certainly, some patients, particularly those with laminin mutations, have worse outcome than others and may require an implantable cardioverter defibrillator, while patients with other forms of dilated cardiomyopathy may not. Thus, while all cases of HFrEF due to a dilated cardiomyopathy were taken together, more recently, splitting has been an achievement in this patient population. Importantly, LVEF is not the main, or only, predictor of outcomes in such patients, because genetic mutations determine whether such patients die of pump failure or die suddenly from fatal arrhythmias or are at risk for both. Indeed, while sudden cardiac death overall is less common in non-ischemic than in ischemic cardiomyopathy (28), the degree of fibrosis, rather than LVEF, might become an important risk predictor for sudden cardiac death. Clearly, LVEF <40% or 35% alone is an insufficient criterion for ICD implantation, particularly in dilated cardiomyopathy. On the contrary, increasing evidence support the prognostic role of myocardial fibrosis (29).

**Beyond ejection fraction**

As LVEF only measures volumes during systole and diastole and is markedly affected by the degree of regurgitation through an increasingly leaky mitral valve, we have to rely on other imaging techniques to correctly assess myocardial performance. New imaging technologies that focus on longitudinal and circumferential strains and other load-independent diameters of pump function may be a genuine advantage in assessing patients with mitral regurgitation beyond LVEF. Furthermore, more advanced...
technique such a diffusion tensor imaging (30) may provide much deeper insights into myocardial performance, for instance, in hypertrophic cardiomyopathy (31) and congenital heart disease (32), and possibly many others, as such imaging technique considers myocardial microstructure, fiber orientation, and strain rather than mere changes in volume.

**Conclusion**

As we move from lumping to splitting, heart failure management becomes more sophisticated and precise for patients and more interesting for physicians. First, we must reconsider the classification of heart failure solely based on LVEF: HFrEF should be defined as an LVEF <60%, as all such patients respond in a similar fashion to current evidenced-based therapy with ACE inhibitors, angiotensin II receptor blockers, ARNI, and beta blockers, mineralocorticoid antagonists, and CRT and ARNI. HFpEF is an early or mild-to-moderate form of HFrEF; not a separate entity, and therefore should be abandoned. Within this spectrum of reduced LVEF, the underlying cause is an increasingly important factor in determining the risk of MACE and the requirements of and response to therapy.

In contrast, patients with HFpEF, i.e., those with LVEF>60%, symptoms of heart failure, and moderately increased natriuretic peptides, are a heterogeneous group that does require further research. At this point, we know that transthyrethin amyloid heart disease is a distinct entity amenable to novel drugs such as tafamidis (33). In addition, for hypertrophic cardiomyopathy, specific drugs such as mavacamten, a cardiac myosin inhibitor, raises hopes in symptomatic patients (34). Patients with hypertensive LV remodeling and HFpEF are rather candidates for aggressive antihypertensive treatment with RAS inhibitors or ARNI. In patients with fibrotic stiff hearts, mineralocorticoid antagonists and, in the future, antifibrotic therapies might be appropriate. Thus, as we move from lumping to splitting, we may provide personalized drug therapy to the benefit of our patients with heart failure.

**Funding:** There was no funding of any kind for this article.

**Conflict of interest:** Outside this work, the author received educational, research grants, and in part honoraria from Abbott, Amgen, Boehringer Ingelheim, BAYER Healthcare, Daichi-Sankyo, Novartis, Sanofi, Servier, and Vifor.

**Peer-review:** Internally peer-reviewed.

**References**

1. Medical Transactions. Published by the College of Physicians, London. Transaction XVI 1785; Volume 3, pp.255-86.
2. Wehner GJ, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN, et al. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? Eur Heart J 2020; 41: 1249-57. [CrossRef]
3. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35. [CrossRef]
4. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342: 1441-6. [CrossRef]
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7. [CrossRef]
6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13. [CrossRef]
7. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-57. [CrossRef]
8. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacs P, et al.; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8. [CrossRef]
9. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17. [CrossRef]
10. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21. [CrossRef]

11. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al.; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-49. [CrossRef]

12. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004. [CrossRef]

13. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383: 1413-24. [CrossRef]

14. McMurray JJ, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al.; DAPA-HF Trial Committees and Investigators. dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995-2008. [CrossRef]

15. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al.; VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020; 382: 1883-93. [CrossRef]

16. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-75. [CrossRef]

17. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al.; GALACTIC-HF Investigators. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med 2020; doi: 10.1056/NEJMoa2025797. Epub ahead of print [CrossRef]

18. Shen L, Jhund PS, Claggett BL, Barlier A, Cleland JGF, et al. Declining Risk of Sudden Death in Heart Failure. N Engl J Med 2017; 377: 41-51. [CrossRef]

19. Lam CSP, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J 2018; 39: 1770-80. [CrossRef]

20. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200. [CrossRef]

21. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-81. [CrossRef]

22. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al.; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-92. [CrossRef]

23. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al.; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016; 37: 455-62. [CrossRef]

24. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al.; PARAGON-HF Investigators and Committees. Angiotensin-Nepriylisin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019; 381: 1609-20. [CrossRef]

25. Vaduganathan M, Jhund PS, Claggett BL, Packer M, Widimsky J, Seferovic P, et al. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. Eur Heart J 2020; 41: 2356-62. [CrossRef]

26. Lüscher TF. Lumpers and splitters: the bumpy road to precision medicine. Eur Heart J 2019; 40: 3292-6. [CrossRef]

27. Haas J, Fresse KS, Peil B, Kloos W, Keller A, Nietsch R, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 2015; 36: 1123-35a. [CrossRef]

28. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al.; DANISH Investigators. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 2016; 375: 1221-30. [CrossRef]

29. Shanhag SM, Greve AM, Aspelund T, Schelbert EB, Cao JI, Danelius R, et al. Prevalence and prognosis of ischaemic and non-ischaemic myocardial fibrosis in older adults. Eur Heart J 2019; 40: 529-38. [CrossRef]

30. Scott AD, Ferreira PF, Nielles-Vallespin S, Gatehouse P, McGill LA, Kilner P, et al. Optimal diffusion weighting for in vivo cardiac diffusion tensor imaging. Magn Reson Med 2015; 74: 420-30. [CrossRef]

31. Schumm J, Greulich S, Wagner A, Grün S, Ong P, Bentz K, Klingel K, Kandolf R, Bruder O, Schneider S, Sechtem U, Mahrholdt H. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J Cardiovasc Magn Reson 2014; 16: 14. [CrossRef]

32. Khlaieque Z, Ferreira PF, Scott AD, Nielles-Vallespin S, Kilner PJ, Kutsy R, et al. Deranged Myocyte Microstructure in Situs Inversus Totalis Demonstrated by Diffusion Tensor Cardiac Magnetic Resonance. JACC Cardiovasc Imaging 2018; 11: 1360-2. [CrossRef]

33. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlino G, Waddington-Cruz M, et al.; ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018; 370: 1007-16. [CrossRef]

34. Olivetto I, Orezia A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al.; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020; 396: 759-69. [CrossRef]